Skip to content

The effectiveness of bupivacaine liposomes in reducing pain after thoracoscopic surgery for erector spinae muscle block

The effectiveness of bupivacaine liposomes in reducing pain after thoracoscopic surgery for erector spinae muscle block

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091687
Enrollment
Unknown
Registered
2024-11-01
Start date
2024-04-23
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary bulla

Interventions

Group Liposome bupivacaine:Liposome bupivacaine
Ropivacaine:Ropivacaine

Sponsors

Mengcheng County First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age range from 18 to 65 years old; 2.BMI: 18-30 kg/m^2; 3.ASA Level I or II; 4.Patients who choose to undergo thoracoscopic surgery;

Exclusion criteria

Exclusion criteria: 1.Infection or skin disease at the puncture site; 2.Poor compliance, inability to complete visual simulation scoring forms, etc; 3.Abnormal heart, lung, liver, kidney, nervous system, and coagulation function; 4.Have a history of allergies to local anesthetics and intraoperative medications; 5.Preoperative use of drugs that affect neurological function; 6.Previously used opioid drugs or antipsychotic drugs;

Design outcomes

Primary

MeasureTime frame
Recovery of pain relief within 24 hours after surgery;Pain Visual Analog Scale (VAS);Intraoperative consumption of remifentanil and sufentanil;First press time of analgesic pump;

Secondary

MeasureTime frame
hemodynamics;The incidence of complications related to ESPB (infection, hematoma, pneumothorax, etc.);The incidence of postoperative nausea and vomiting;Record whether ephedrine or atropine is used;

Countries

China

Contacts

Public ContactShuang Li; Xiaoqiang Zhang

Mengcheng County First People's Hospital

cool1860@126.com+86 558 7623591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026